“Cost-effectiveness analysis of empagliflozin in the treatment of patients with type 2 diabetes and established cardiovascular disease in Italy, based on the results of the EMPA-REG OUTCOME study” (2017) Farmeconomia. Health economics and therapeutic pathways, 18(1). doi:10.7175/fe.v18i1.1332.